6838.TW Formosa Pharmaceuticals, Inc.

Healthcare Biotechnology Taiwan Stock Exchange
21.00 TWD
Close of Nov 6, 2026
20.70 33.30
Market cap
TWD 3.17B
P/E
-
P/B
2.31x
ROE
-12.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6838.TW undervalued?

Graham number

The Graham number of Formosa Pharmaceuticals, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Formosa Pharmaceuticals, Inc. fundamental analysis

No fundamental analysis for Formosa Pharmaceuticals, Inc. yet.

Formosa Pharmaceuticals, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Formosa Pharmaceuticals, Inc.

Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- hist…

Full company profile